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AUC‐Pi

:   area under the concentration‐time curve of plasma phosphate

C

:   CONTROL (denomination of treatment group)

\[Ca\]

:   concentration of calcium

\[Mg\]

:   concentration of magnesium

MgP

:   group treated with MgHPO~4~ (denomination of treatment group)

NaP

:   group treated with NaH~2~PO~4~ (denomination of treatment group)

Na~2~P

:   group treated with Na~2~HPO~4~ (denomination of treatment group)

P

:   phosphorus

Pi

:   phosphate

\[Pi\]

:   concentration of phosphate

Pi‐C~max~

:   peak concentration of plasma phosphate

Pi‐C~max‐model~

:   peak concentration of plasma phosphate derived from a model

ΔPi‐C~max~

:   peak concentration of plasma phosphate increment

ΔPi‐C~max‐model~

:   peak concentration of plasma phosphate increment derived from a model

Pi‐T~max~

:   time to peak concentration of plasma phosphate

Pi‐T~max‐model~

:   time to peak concentration of plasma phosphate derived from a model

\[TP\]

:   total protein concentration

1. INTRODUCTION {#jvim15094-sec-0006}
===============

Hypophosphatemia in dairy cows is thought to be associated with an increased risk of disease and impaired productivity particularly in early lactation.[1](#jvim15094-bib-0001){ref-type="ref"} It not only has been linked to decreased feed intake and productivity but is also believed to cause or contribute to periparturient conditions of the dairy cow such as the downer cow syndrome or postparturient hemoglobinuria.[2](#jvim15094-bib-0002){ref-type="ref"}, [3](#jvim15094-bib-0003){ref-type="ref"} The incidence of periparturient hypophosphatemia even in clinically healthy dairy cows is considerable. Metabolic profiling studies reported incidences of subnormal plasma phosphate concentrations (\[Pi\]) on the day of calving of above 50% and of 10%‐15% in the first two weeks of lactation.[1](#jvim15094-bib-0001){ref-type="ref"} The relevance of this periparturient hypophosphatemia remains disputed as it is frequently not associated with clinical signs such as recumbency and postparturient hemoglobinuria. It is the reason for which phosphorus (P) supplementation is recommended and practiced particularly in fresh cows.[2](#jvim15094-bib-0002){ref-type="ref"}, [4](#jvim15094-bib-0004){ref-type="ref"}, [5](#jvim15094-bib-0005){ref-type="ref"}

Treatment recommendations published over the past decades often favor IV bolus administration of solutions containing phosphate (Pi) salts.[2](#jvim15094-bib-0002){ref-type="ref"}, [6](#jvim15094-bib-0006){ref-type="ref"}, [7](#jvim15094-bib-0007){ref-type="ref"}, [8](#jvim15094-bib-0008){ref-type="ref"} This approach however has raised concerns for several reasons. First in most countries of the world there are no commercial Pi‐containing solutions available that are labeled for the parenteral use in farm animals, making this approach an off‐label treatment. Products containing P in a form different and not convertible to Pi seem to be unsuitable for the correction of hypophosphatemia.[1](#jvim15094-bib-0001){ref-type="ref"}, [4](#jvim15094-bib-0004){ref-type="ref"} Secondly bolus infusion of Pi‐salt solutions results in a pronounced but short lived increase of plasma \[Pi\] above the reference range.[6](#jvim15094-bib-0006){ref-type="ref"} The poor solubility of Pi may result in complexing of Pi with divalent cations such as calcium or magnesium in plasma thereby causing a decline of the plasma calcium (\[Ca\]) and magnesium concentration (\[Mg\]), which presents a concern particularly in early lactation.[2](#jvim15094-bib-0002){ref-type="ref"}, [9](#jvim15094-bib-0009){ref-type="ref"} Thirdly the plasma \[Pi\] returns to baseline values within two to three hours after administration, making this treatment unsuitable to be used as stand‐alone treatment of hypophosphatemia.[6](#jvim15094-bib-0006){ref-type="ref"}

Oral treatment of P‐depleted cows with Pi salts slightly delays onset of action when compared with IV treatment but the treatment is easy to administer and has as an effect lasting for 12--24 hours.[6](#jvim15094-bib-0006){ref-type="ref"}, [9](#jvim15094-bib-0009){ref-type="ref"}, [10](#jvim15094-bib-0010){ref-type="ref"} Currently, a variety of Pi‐containing salts are recommended and used for the oral treatment of hypophosphatemia in cattle, but studies comparing these salts in their efficacy to correct hypophosphatemia are scant.[1](#jvim15094-bib-0001){ref-type="ref"}, [2](#jvim15094-bib-0002){ref-type="ref"}, [8](#jvim15094-bib-0008){ref-type="ref"} Therefore, the objective of this study was to compare different Pi‐salts commonly used in the field in their treatment efficacy for the correction of hypophosphatemia in dairy cows. The salts to be compared were monosodium dihydrogen phosphate (NaH~2~PO~4~), disodium monohydrogen phosphate (Na~2~HPO~4~), and magnesium phosphate (MgHPO~4~). We hypothesized that the efficacy for the correction of hypophosphatemia of these salts is primarily driven by their solubility characteristics. We therefore anticipated most rapid and pronounced effects for the most soluble NaH~2~PO~4~ followed by Na~2~HPO~4~ while a weaker and more delayed effect was expected for the poorly soluble MgHPO~4~.

2. MATERIALS AND METHODS {#jvim15094-sec-0007}
========================

2.1. Animals, housing, and feeding {#jvim15094-sec-0008}
----------------------------------

The national and institutional guidelines for the care and use of experimental animals were followed and all experimental procedures were approved by the Utrecht University Institutional Animal Care and Use Committee (AVD108002016616).

Twelve clinically healthy Holstein Friesian cows in their fourth week of lactation were used for this study. Cows were between 3 and 6.5 years old and in their second to fifth lactation. All animals were healthy on the basis of physical examination despite of pronounced hypophosphatemia. Cows were housed in tie‐stalls with rubber bedding covered with saw dust in a temperature controlled environment.

Prior and during the experimental treatment enrolled cows were fed a Total Mixed Ration that was markedly phosphorus deficient, but that otherwise met currently used nutrient recommendations for dry and lactating dairy cows for a period of ∼8 weeks.[11](#jvim15094-bib-0011){ref-type="ref"} The dry cow ration that was offered for 4 weeks before the expected calving date contained ∼0.13% P in DM and the ration fed after calving contained ∼0.18% P in DM. The dietary P content was thus ∼50% below requirement during the late dry period and at least 40% below the recommended daily dietary supply after parturition.[11](#jvim15094-bib-0011){ref-type="ref"} Cows were fed and milked twice daily between 0600 and 0700 hours and 1800 and 1900 hours. The daily milk yield during the experimental treatment period ranged between 25 and 32 kg/day, daily feed intake ranged between 13 and 18 kg DM.

2.2. Experimental study {#jvim15094-sec-0009}
-----------------------

All cows received a sham treatment serving as control and were thereafter assigned to 1 of 3 experimental treatments by randomization. The wash‐out period between control and treatment was between 24 and 48 hours. Treatments consisted in a single oral administration of either plain water (sham treatment, group C, n = 12) or the equivalent of 60 g P in the form of monosodium dihydrogen phosphate (302 g NaH~2~PO~4~ × 2H~2~O, group NaP, n = 4), disodium monohydrogen phosphate (345 g Na~2~HPO~4~ × 2H~2~O, group Na~2~P, n = 4) or magnesium hydrogen phosphate (338 g MgHPO~4~ × 3H~2~O, group MgP, n = 4). The salt was dissolved in 2 L of warm (∼38°C) water and was administered by orogastric tube. Treatments were administered at standardized times between 0800 and 0830 hours. Sham treatment always preceded the experimental treatment. This approach was used because of the high individual variability of the treatment effect of PO administered Pi observed in earlier studies and the resulting difficulty to determine an adequate wash‐out period for the treatment. For blood sampling a 16 G catheter (Angiocath; Becton Dickinson, Heidelberg, Germany) connected to an extension set (Discofix C‐3, 10 cm; Braun Melsungen AG, Melsungen, Germany) was placed aseptically in a jugular vein the evening before the sham treatment.

Blood samples were collected immediately before treatment or sham administration (0) and again 30, 60, 90, 120, 180, 240, 300, 420, 720, and 1440 minutes after treatment. Blood was collected in 10 mL tubes containing lithium heparin as anticoagulant and kept at room temperature until processed. Samples were centrifuged within 10 min at 1600*g* for 15 minutes. Plasma was then harvested and stored at −20°C until analyzed.

2.3. Biochemical analysis {#jvim15094-sec-0010}
-------------------------

The plasma \[Pi\], \[Mg\], and \[Ca\] were analyzed photometrically (ammonium molybdate, xylidyl blue, and Arsenazo III, respectively) on an automated analyzer (ABX Pentra 400; Horiba, Europe GmbH, Langenhagen, Germany). Total protein concentration (\[TP\]) was measured by refractometry using a temperature corrected refractometer.

2.4. Data analysis {#jvim15094-sec-0011}
------------------

For each animal, the maximum plasma \[Pi\] (Pi‐*C* ~max~) and the time to maximum plasma \[Pi\] (Pi‐*T* ~max~) were derived from its individual concentration − time plot. The area under the curve of plasma \[Pi\] (AUC‐Pi) was calculated using the trapezoidal rule. The peak increment of plasma \[Pi\] was determined for each study animal by subtracting the baseline plasma \[Pi\] from the peak concentration of the electrolyte in question (ΔPi‐*C* ~max~). The same approach was used for \[Mg\] in animals of group MgP.

Plasma \[Pi\] at *T~i~* was furthermore corrected for the change in plasma \[TP\] on a percent basis occurring between *T* ~0~ and *T~i~* as described earlier.[12](#jvim15094-bib-0012){ref-type="ref"} This approach was used to assess changes of plasma volume that may have occurred during the observation and may have affected the plasma \[Pi\] or \[Mg\].

To improve the precision of the estimation of ΔPi‐*C* ~max~ and Pi‐*T* ~max~ the plasma \[Pi\] for the treatment curves were modeled as log‐normal distribution such that *f* = *y*0 + *y*•*e* ^−0,5^\*^(ln(^ ^*x*^ ^/^ ^*x*^ ^0)/^ ^*b*^ ^) \^ 2)/^ ^*x*^ using a plotting software package (Sigma Plot 12.5; Systat Software, San Jose, California). ΔPi‐*C* ~max‐model~ and Pi‐*T* ~max‐model~ were then derived from the respective functions for each treatment group.

2.5. Statistical analysis {#jvim15094-sec-0012}
-------------------------

Results are expressed as mean and SD or as median and interquartile range (IQR) for variables that were not normally distributed. Normality of distribution was checked by Shapiro‐Wilk\'s test for normality distribution and by checking normal probability plots. Log transformations were used wherever appropriate to obtain normal distribution. Repeated measurements ANOVAs were conducted to determine treatment, time, and interaction of time and treatment effects using an autoregressive model with Cow ID as subject. Post hoc tests were used whenever *F*‐test was significant. Bonferroni‐corrected *P* values were used and a *P* \< .05 was considered statistically significant. A statistical software package was used for all analyses (SAS 9.2; SAS Institute, Cary, North Carolina).

3. RESULTS {#jvim15094-sec-0013}
==========

All cows tolerated the assigned oral treatment well and remained healthy without any apparent adverse effects.

The plasma \[Pi\]‐time curves stratified by group are presented in Figure [1](#jvim15094-fig-0001){ref-type="fig"}. All cows included in the study presented pronounced hypophosphatemia immediately before treatment (NaP: 1.27 mg/dL \[0.41 mmol/L\], Na~2~P: 1.38 mg/dL \[0.45 mmol/L\], MgP: 1.44 mg/dL \[0.47 mmol/L\], C: 1.30 mg/dL \[0.42 mmol/L\]), which is notably beneath reference range of 4--8 mg/dL or 1.4‐2.6 mmol/L.[13](#jvim15094-bib-0013){ref-type="ref"} Baseline plasma \[Pi\] did not differ between groups.

![Plasma phosphorus concentration‐time curve (median and IQR) stratified by treatment groups: group NaP (treatment with NaH~2~PO~4~, solid line; n = 4), group Na~2~P (treatment with Na~2~HPO~4,~ dashed dotted line; n = 4), group MgP (treatment with MgHPO~4~, dotted line; n = 4), and group C (control group, dashed line; n = 12). Time points marked with\* differ significantly from *T* ~0~. Values marked with different lowercase letters at a specific time point differ significantly between groups (*P* \< .05; Bonferroni corrected). Data of groups NaP and MgP are slightly offset with respect to time to improve readability. Reference range for plasma phosphorus in cattle: 4--8 mg/dL.^13^ C, control, MgP, treatment with MgHPO~4~, NaP, treatment with NaH~2~PO~4~, Na~2~P, treatment with Na~2~HPO~4~](JVIM-32-1253-g001){#jvim15094-fig-0001}

The ANOVA revealed a significant treatment effect, with all treatment groups differing from control and MgP differing from NaP and Na~2~P. Although the plasma \[Pi\] in group NaP was numerically higher than in Na~2~P at various time points the difference was not significant at any time. Time effects were apparent in all groups except control.

The plasma \[Pi\] tended to increase within 30 minutes of treatment in groups NaP and Na~2~P with significantly increased values relative to baseline 60 minutes after treatment (NaP: *P =* .0044; Na~2~P: *P =* .0077*)*. The Pi‐*T* ~max~ was 420 and 360 minutes after treatment with a peak increment of 5.33 mg/dL (1.72 mmol/L) and 4.30 mg/dL (1.39 mmol/L) in group NaP and Na~2~P, respectively (Table [1](#jvim15094-tbl-0001){ref-type="table-wrap"}). The plasma \[Pi\]‐time curve of group MgP revealed a very flat increase with values differing from baseline only after 300 minutes and a Pi‐*T* ~max~ of 860 minutes with a maximum plasma \[Pi\] increment of 3.19 mg/dL (1.03 mmol/L, Table [1](#jvim15094-tbl-0001){ref-type="table-wrap"}). As expected no time effect on plasma \[Pi\] was observed in the control group. The median plasma \[Pi\] reached the reference range between 120 and 180 minutes after treatment in groups NaP and Na~2~P and after 720 minutes in group MgP. The plasma \[Pi\] remained markedly increased compared with baseline values until the end of the observation period at 24 hours post treatment in all three treatment groups.

###### 

Median and IQR of peak increment of plasma Pi concentrations (ΔPi‐*C* ~Max~), time to peak increment of plasma Pi concentration (ΔPi‐*T* ~Max~), and area under the concentration‐time curve of plasma Pi concentration increment (ΔPi‐AUC) stratified by group

                            C                        MgP                         NaP                          Na~2~P
  --------------- --------- ------------------------ --------------------------- ---------------------------- -----------------------------
  ΔPi‐*C* ~Max~   mg/dL     0.06^a^ \[0.03--0.25\]   3.19^b^ \[2.11--4.04\]      5.33^b^ \[5.26--5.35\]       4.3^b^ \[3.59--4.68\]
  Pi‐*T* ~Max~    min       300 \[135--1080\]        1440 \[1080--1440\]         420 \[420--570\]             360 \[270--420\]
  Pi‐AUC          mg\*h/L   0.68^a^ \[--0.68‐3.5\]   54.17^b^ \[37.54--66.96\]   93.48^c^ \[82.07--101.04\]   78.94^a,b^ \[74.73--85.97\]

Values with different superscript letters within a row were significantly different (*P* \< .05, Bonferroni corrected). C, control, MgP, treatment with MgHPO~4~, NaP, treatment with NaH~2~PO~4~, Na~2~P, treatment with Na~2~HPO~4~.

Analysis of the protein corrected plasma \[Pi\] and comparison with uncorrected plasma \[Pi\] did not reveal any effect attributable to plasma volume changes (data not shown).

Table [1](#jvim15094-tbl-0001){ref-type="table-wrap"} summarizes the peak increment of plasma \[Pi\] (Pi‐Δ*C* ~max~), Pi‐*T* ~max~, and the AUC‐Pi, values determined from the modeled plasma \[Pi\]‐time curves are shown in Table [2](#jvim15094-tbl-0002){ref-type="table-wrap"}. The AUC‐Pi was the largest in group NaP but differed only numerically from group Na~2~P. The AUC‐Pi of group MgP was 50% of group NaP.

###### 

Peak increments of plasma Pi concentrations (ΔPi‐*C* ~Max‐model~) and time to peak increments of plasma Pi concentrations (Pi‐*T* ~Max‐model~) derived from log normal distribution models (*f* = *y*0 + *y*•e ^−0,5\*(ln(^ ^*x*^ ^/^ ^*x*^ ^0)/^ ^*b*^ ^) \^ 2)/^ ^*x*^) developed for each treatment group

                                  MgP     NaP     Na~2~P
  --------------------- --------- ------- ------- --------
  ΔPi‐*C* ~Max‐model~   mg/dL     3.31    4.99    4.21
  Pi‐*T* ~Max‐model~    min       860     445     460
  Goodness of fit       *R* ^2^   0.997   0.981   0.991

Goodness of fit characterized by *R* ^2^ is given for the model developed for each of the three treatment groups. MgP, treatment with MgHPO~4~, NaP, treatment with NaH~2~PO~4~, Na~2~P, treatment with Na~2~HPO~4~.

Treatment with MgHPO~4~ led to significant differences between group MgP and C (240--720 minutes) and MgP and Na~2~P (420--720 minutes) in plasma \[Mg\] (Figure [2](#jvim15094-fig-0002){ref-type="fig"}).

![Mean and SD of plasma magnesium concentration increments to baseline after treatment stratified by groups: group NaP (treatment with NaH~2~PO~4~, solid line; n = 4), group Na~2~P (treatment with Na~2~HPO~4,~ dashed dotted line; n = 4), group MgP (treatment with MgHPO~4~, dotted line; n = 4), and group C (control group, dashed line; n = 12). Values marked with different lowercase letters at a specific time point differ significantly between groups (*P* \< .05; Bonferroni corrected). Data of groups NaP and MgP are slightly offset with respect to time to improve readability. C, control, MgP, treatment with MgHPO~4~, NaP, treatment with NaH~2~PO~4~, Na~2~P, treatment with Na~2~HPO~4~](JVIM-32-1253-g002){#jvim15094-fig-0002}

Plasma \[Ca\] neither showed a significant time nor treatment effect (data not shown).

4. DISCUSSION {#jvim15094-sec-0014}
=============

After oral treatment of markedly phosphorus deficient cows with 1 of 3 different Pi containing salts (NaH~2~PO~4~, Na~2~HPO~4~, or MgHPO~4~) the increase in plasma \[Pi\] was most pronounced in group NaP, followed by Na~2~P. The increment of plasma \[Pi\] in group MgP was considerably flatter and delayed in time. We suggest that solubility characteristics of the salts used plays a central part in oral availability for resorption.

The main objective of the present study was to compare the efficacy of different Pi containing salts for the treatment of hypophosphatemia in dairy cows. The addressed question is relevant as the expectation of an oral treatment with Pi‐salts to rapidly correct acute hypophosphatemia in cows is inherently different from the use of Pi‐salts used as feed additives to supplement P‐deficient diets. An oral treatment for the correction of hypophosphatemia that is suitable to replace or at least complement parenteral P‐supplementation should have a rapid onset of action and a sustained effect lasting for at least 24 hours. For example, earlier studies revealed that dicalcium phosphate, a salt widely used for the supplementation of P‐deficient ruminant rations, is poorly suited for the rapid correction of hypophosphatemia.[6](#jvim15094-bib-0006){ref-type="ref"}, [9](#jvim15094-bib-0009){ref-type="ref"} Another interesting observation is that the preference of different Pi containing salts varies by geographic regions for no apparent reason. While monosodium phosphate is widely used for the treatment of hypophosphatemia in the Americas, in Europe disodium phosphate is widely marketed for the oral treatment of cattle.[2](#jvim15094-bib-0002){ref-type="ref"}, [5](#jvim15094-bib-0005){ref-type="ref"}, [14](#jvim15094-bib-0014){ref-type="ref"}

Baseline plasma \[Pi\] determined in this study were consistent with pronounced hypophosphatemia and without difference between treatment groups, confirming that the dietary P‐depletion protocol used before application of the experimental treatment was appropriate to induce hypophosphatemia. A rapid and sustained effect on the plasma \[Pi\] was observed for both sodium phosphate salts with significant effects detectable within 1 hour, peak concentrations occurring after six to seven hours and an effect sustained for over 24 hours (Figure [1](#jvim15094-fig-0001){ref-type="fig"} and Table [1](#jvim15094-tbl-0001){ref-type="table-wrap"}). In both groups, the low end of the reference range of plasma \[Pi\] was reached within 2--3 hours and maintained for 24 hours after treatment. Differences between group NaP and Na~2~P were not significant suggesting a similar effect of NaH~2~PO~4~ compared with Na~2~HPO~4~. This is remarkable as both salts differ considerably in their solubility characteristics. Na~2~HPO~4~ has a relatively low solubility of 7.7 g/dL water[15](#jvim15094-bib-0015){ref-type="ref"} compared with NaH~2~PO~4~ with 85 g/dL water at 20°C.[16](#jvim15094-bib-0016){ref-type="ref"} The low sample size of four animals per treatment group in this study likely resulted in insufficient statistical power to reveal the moderate difference between the treatments with NaH~2~PO~4~ and Na~2~HPO~4~.

The treatment effect with NaH~2~PO~4~ reported in this study differs from results of other studies conducted in cattle having used similar doses of NaH~2~PO~4~.[9](#jvim15094-bib-0009){ref-type="ref"}, [10](#jvim15094-bib-0010){ref-type="ref"} In these studies, a less pronounced effect on the plasma \[Pi\] was reported with increases in the range of only 3 mg/dL (1 mmol/L), while peak concentrations were reached sooner, between 4 and 5 hours after treatment. It is probable that this difference between studies is attributable to the much more pronounced hypophosphatemia in this study that was achieved through a considerably longer duration of dietary P‐depletion. The degree of stimulation of enteral Pi‐absorption is associated with the degree of P‐deprivation.[17](#jvim15094-bib-0017){ref-type="ref"} Stronger stimulation of enteral P uptake is therefore likely to have contributed to higher peak plasma \[Pi\] values and could also explain delayed peaks through prolonged absorption.

Discrepancies between this and other studies also exist for the effect of Na~2~HPO~4~. An older study used Na~2~HPO~4~ to treat dairy cows but reported no effect.[8](#jvim15094-bib-0008){ref-type="ref"} The lack of effect of oral Na~2~HPO~4~ reported in that study might however be attributable to the use of dairy cows that were not P‐deprived, which might have resulted in considerably lower absorption rates of dietary P.

The oral treatment with MgHPO~4~ in this study was markedly less effective in the timely correction of hypophosphatemia. A significant effect on the plasma \[Pi\] was apparent only five hours after treatment, with peak concentrations occurring 14 hours after treatment and peak increments of plasma \[Pi\] that were considerably lower than in the groups treated with sodium phosphate salts. We attribute this protracted effect on the plasma \[Pi\] to the low solubility of MgHPO~4~ (0.025 g/dL water at 20°C).[18](#jvim15094-bib-0018){ref-type="ref"} MgHPO~4~ has been reported to precipitate to quanite (NH~4~MgHPO~4~) in the rumen of sheep, a reaction if also occurring in cattle could have further contributed to impaired bioavailability of this compound.[19](#jvim15094-bib-0019){ref-type="ref"} There are similar poor effects on the plasma \[Pi\] for dicalcium phosphates another phosphate salt with very low solubility in water.[6](#jvim15094-bib-0006){ref-type="ref"}, [9](#jvim15094-bib-0009){ref-type="ref"} Both, dicalcium phosphate and MgHPO~4~ must be considered unsuitable for rapid correction of hypophosphatemia through oral treatment as drench or bolus and are probably more suited as feed additives to supplement P‐deficient diets on a long term.

Treatment with MgHPO~4~ in this study led to increases in plasma \[Mg\] in the range of 0.3 mg/dL (0.12 mmol/L) compared with the group C. It should be noted that control and treatment groups had plasma \[Mg\] within the reference range at all times (1.7‐3.0 mg/dL; 0.7‐1.23 mmol/L).[13](#jvim15094-bib-0013){ref-type="ref"} The delayed effect on plasma \[Mg\] matches the slope of the plasma \[Pi\] in the animals treated with MgHPO~4~, which corroborates the assumption that the absorption of this salt is hampered by its very limited solubility and possibly precipitates in ruminal fluid.[19](#jvim15094-bib-0019){ref-type="ref"}

Supplementation of large oral doses of P was reported to impair the apparent absorption of Mg in animals that were not P‐deficient.[20](#jvim15094-bib-0020){ref-type="ref"}, [21](#jvim15094-bib-0021){ref-type="ref"} It has thus been suggested that in states of limited availability of dietary Mg excessive supply of oral P might increase the risk for hypomagnesemic tetany.[20](#jvim15094-bib-0020){ref-type="ref"} In contrast, in states of low dietary P‐supply it was found that the supplementation of P can enhance transruminal Mg‐absorption in isolated rumen of sheep.[22](#jvim15094-bib-0022){ref-type="ref"} In this study, treatment with sodium phosphate salts had no effect on the plasma \[Mg\], which suggests that a single treatment with oral monosodium‐ or disodium phosphate does not cause a relevant disturbance of the Mg balance in treated animals. This is in agreement with an earlier study investigating the effect of a single oral dose of different phosphate salts in hypophosphatemic dairy cows.[10](#jvim15094-bib-0010){ref-type="ref"}

5. CONCLUSIONS {#jvim15094-sec-0015}
==============

In conclusion a single oral treatment with NaH~2~PO~4~ or Na~2~HPO~4~ providing the equivalent of 60 g P is adequate for the timely correction of hypophosphatemia in cattle. The treatment has a rapid onset of action and a sustained effect. Oral administration of MgHPO~4~ has a considerably protracted effect on the plasma \[Pi\] and is therefore not recommended to be used as drench or bolus in animals requiring rapid correction of blood \[Pi\].
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